All In Biotech

Drug Trial Radar · NCT06922448

Study of BLU-808 in Allergic Rhinoconjunctivitis

A Phase 2a Randomized Double-blinded Placebo Controlled Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Clinical Activity of BLU-808, a Wild-type KIT Inhibitor, in Participants With Ragweed (Ambrosia Artemisiifolia)-Induced Allergic Rhinoconjunctivitis

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Apr 14, 2025

Primary completion

Sep 8, 2025

Study completion Sep 8, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic rhinoconjunctivitis (ARC). Participants will undergo eligibility assessments that include exposure to ragweed pollen in an allergen exposure chamber (AEC).

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

  • BLU-808Drug

    BLU-808 tablets

  • PlaceboDrug

    Placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 through Day 56

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Red Maple Trials

    Ottawa, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.